The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
To rechallenge or not to rechallenge? Immune-checkpoint inhibitor–associated neurotoxicity in advanced melanoma patients.
 
Muhammad Jaffer
No Relationships to Disclose
 
Nikhil Khushalani
Stock and Other Ownership Interests - Bellicum Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; Delcath Systems; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Merck; Mural Oncology; Nektar; Novartis; Regeneron; Replimune; Sun Pharma
Research Funding - BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); HUYA Bioscience International (Inst); IDEAYA Biosciences (Inst); Merck (Inst); Modulation Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Castle Biosciences; Regeneron
Other Relationship - Bristol-Myers Squibb/Celgene; Nektar; Regeneron; Replimune; Sun Pharma
(OPTIONAL) Uncompensated Relationships - T-Knife
 
David Iacono
No Relationships to Disclose
 
Peter Forsyth
No Relationships to Disclose
 
Yolanda Pina
No Relationships to Disclose
 
Sepideh Mokhtari
No Relationships to Disclose
 
Edwin Peguero
No Relationships to Disclose
 
Husayn Jaffer
No Relationships to Disclose
 
Ahmad Tarhini
Consulting or Advisory Role - AstraZeneca; Bayer; BioNTech; Bristol-Myers Squibb; Clinigen Group; ConcertAI; Eisai; Genentech/Roche; Instil Bio; Merck; Moderna Therapeutics; Nested; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Agenus (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); Nested Therapeutics (Inst); OncoResponse (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Scholar Rock (Inst); Werewolf Therapeutics (Inst)
 
Joseph Markowitz
Stock and Other Ownership Interests - Amdocs; Consolidated Edison
Consulting or Advisory Role - Newlink Genetics
Research Funding - Idera (Inst); Merck (Inst); Morphogenesis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on development of Inhibitors for S100B (Inst); Pending patent on flow cytometry analysis system (Inst); Pending patent on the role of nitric oxide in melanoma. (Inst)
Other Relationship - Springer
 
Lilit Karapetyan
Research Funding - Iovance Biotherapeutics (Inst); Valar Labs (Inst)
Travel, Accommodations, Expenses - immatics
 
Zeynep Eroglu
Consulting or Advisory Role - Natera; Pfizer; Regeneron; Replimune; Sun Pharma
Research Funding - Boehringer Ingelheim (Inst); Pfizer (Inst)
 
Andrew Brohl
Consulting or Advisory Role - Deciphera
Research Funding - Merck (Inst)
 
Ali-Musa Jaffer
No Relationships to Disclose